RxDoctor Payments Data

Kimberly Sivertsen

Nurse Practitioner · Madison, WINPI 1891054060

Payments from drug & device makers

$2,015in general payments, 2019–2025

Across 42 payments — averaging $47.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$684
  • Intuitive Surgical$392
  • AstraZeneca$202
  • GSK$165
  • Grifols USA, LLC$151
  • Amgen$128
  • plus $293 from 5 others

What the payments were for

  • Consulting fees$52026%
  • Travel & lodging$39219%
  • Food & beverage$1,10255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,015 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,078
Medicare patients
79
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$43,351
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$41,494
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$22,672
Incruse ElliptaUmeclidinium Bromide35$13,209
Breo ElliptaFluticasone/Vilanterol23$10,329
Spiriva HandihalerTiotropium Bromide14$9,430
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$9,357
Albuterol Sulfate HfaAlbuterol Sulfate62$1,900
Ventolin HfaAlbuterol Sulfate12$649
Azithromycin11$228
Prednisone13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$165$87,703146 claims
AstraZenecaBreztri Aerosphere$202$43,35149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →